Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Laboratory Corporation Of America Holdings (LH)
NYSE:LH
Laboratory (LH) Stock Price & Analysis
981 Followers
LH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$177.78 - $233.32
Previous Close$210.59
Volume730.92K
Average Volume (3M)789.90K
Market Cap
$17.75B
Enterprise Value$23.17B
Total Cash (Recent Filing)$536.80M
Total Debt (Recent Filing)$5.95B
Price to Earnings (P/E)42.5
Beta0.86
Next Earnings
Jul 25, 2024EPS Estimate
$3.81Next Dividend Ex-Date
May 24, 2024Dividend Yield1.37%
Share Statistics
EPS (TTM)4.95
Shares Outstanding84,293,628
10 Day Avg. Volume680,600
30 Day Avg. Volume789,899
Standard Deviation0.08
R-Squared0.40
Alpha-0.00262
Financial Highlights & Ratios
Price to Book (P/B)-11.16
Price to Sales (P/S)7.74
Price to Cash Flow (P/CF)7.80
P/FCF Ratio6.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.91
Enterprise Value/Gross Profit6.89
Enterprise Value/Ebitda15.67
Forecast
1Y Price Target
$245.38Price Target Upside16.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Laboratory News
PremiumCompany Announcements
Labcorp Announces Live Stream of Shareholders’ Meeting
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnalyst recommends the stock based on LabCorp's strong financial performance, highlighted by a robust 7.5% year-over-year revenue increase in the Biopharma Laboratory Services segment and a significant 35.7% rise in adjusted operating income.
Operational EfficiencyLabCorp's commitment to the LaunchPad initiative is expected to generate substantial savings between $100-$125 million, which is anticipated to contribute to margin expansion in the coming year.
Strategic AcquisitionsThe strategic acquisition of select assets from BioReference Health is anticipated to enhance LabCorp's operational footprint with 10 additional laboratory facilities and over 60 patient service centers, thereby supporting the company's growth trajectory.
Bears Say
Acquisition ImpactThe acquisition of Invitae is initially causing dilution in shareholder value, raising concerns among investors.
Business Segment PerformanceThe company's Early Development segment is facing significant challenges due to higher than expected cancellations, leading to revenue declines.
Regulatory ConcernsAnticipation of new FDA rules on lab-developed tests and potential PAMA returns is causing unease among investors, casting a shadow over the stock's prospects.
---
Ownership Overview
1.47% Insiders
29.71% Mutual Funds
46.01% Other Institutional Investors
22.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LH FAQ
What was Laboratory Corporation Of America Holdings’s price range in the past 12 months?
Laboratory Corporation Of America Holdings lowest stock price was $177.78 and its highest was $233.32 in the past 12 months.
What is Laboratory Corporation Of America Holdings’s market cap?
Currently, no data Available
When is Laboratory Corporation Of America Holdings’s upcoming earnings report date?
Laboratory Corporation Of America Holdings’s upcoming earnings report date is Jul 25, 2024 which is in 67 days.
How were Laboratory Corporation Of America Holdings’s earnings last quarter?
Laboratory Corporation Of America Holdings released its earnings results on Apr 25, 2024. The company reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.484 by $0.196.
Is Laboratory Corporation Of America Holdings overvalued?
According to Wall Street analysts Laboratory Corporation Of America Holdings’s price is currently Undervalued.
Does Laboratory Corporation Of America Holdings pay dividends?
Laboratory Corporation Of America Holdings pays a Quarterly dividend of $0.72 which represents an annual dividend yield of 1.37%. See more information on Laboratory Corporation Of America Holdings dividends here
What is Laboratory Corporation Of America Holdings’s EPS estimate?
Laboratory Corporation Of America Holdings’s EPS estimate is $3.81.
How many shares outstanding does Laboratory Corporation Of America Holdings have?
Laboratory Corporation Of America Holdings has 84,293,625 shares outstanding.
What happened to Laboratory Corporation Of America Holdings’s price movement after its last earnings report?
Laboratory Corporation Of America Holdings reported an EPS of $3.68 in its last earnings report, beating expectations of $3.484. Following the earnings report the stock price went down -4.612%.
Which hedge fund is a major shareholder of Laboratory Corporation Of America Holdings?
Among the largest hedge funds holding Laboratory Corporation Of America Holdings’s share is Diamond Hill Capital Management Inc. It holds Laboratory Corporation Of America Holdings’s shares valued at 340M.
---
Laboratory Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$245.38 (16.52% Upside)
$245.38 (16.52% Upside)
Blogger Sentiment
Bullish
LH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 556.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.06%
12-Months-Change
Fundamentals
Return on Equity
4.36%
Trailing 12-Months
Asset Growth
-18.16%
Trailing 12-Months
Company Description
Laboratory Corporation Of America Holdings
Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment involves in providing drug development solutions, to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.
---
LH Company Deck
---
LH Earnings Call
Q1 2024
0:00 / 0:00
---
LH Revenue Breakdown
77.42% Dx
22.81% BLS
---
LH Stock 12 Month Forecast
Average Price Target
$245.38
▲(16.52% Upside)
Technical Analysis
Best Analysts Covering LH
1 Year
1 Year Success Rate
14/18 ratings generated profit
1 Year Average Return
+14.83%
reiterated a buy rating 5 days ago
Copying Erin Wright's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +14.83% per trade.
---